Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema flare predictor device tested in new study

NCT ID NCT07645820

Knowledge-focused Sponsor: Castle Biosciences Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study is testing a handheld device called Nevisense Go to see if it can predict eczema (atopic dermatitis) flares before they become visible or cause symptoms. About 450 people aged 12 to 89 with a history of eczema flares will use the device at home for 90 days. The goal is to develop an algorithm that can estimate the likelihood of a flare based on skin barrier measurements.

Why investors are watching

Castle Biosciences is testing its Nevisense Go device in 450 people with atopic dermatitis to see if skin measurements taken at home can predict a flare before it becomes visible. For a small company, this trial could expand its product beyond its current skin-cancer focus into a new, larger market for chronic skin disease management.

If it works: If the device reliably detects early signs of flares, Castle Biosciences could gain a new commercial product for patients and dermatologists, potentially broadening its revenue base beyond its existing tests.

If it fails: The trial may fail to show that the device predicts flares accurately, or the study could face delays. Clinical trials often fail, and a negative result would likely hurt the company's prospects for this product.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adolescents and adults aged 12 to 89 years with a documented diagnosis of atopic dermatitis and a recent history of disease flares. The multicenter design is intended to support enrollment of a demographically diverse participant population representative of individuals with atopic dermatitis in the United States.

Ages

12 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants may be eligible if they: * Are 12 to 89 years old. * Have been diagnosed with atopic dermatitis (eczema). * Have had at least one atopic dermatitis flare within the past 2 months. * Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits. * If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study. Exclusion Criteria: Participants may not be eligible if they: * Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements. * Do not have suitable skin areas for study measurements. * Have another skin condition that may affect study assessments. * Are pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Dermatology and Cosmetic Surgery - Henderson

    RECRUITING

    Henderson, Nevada, 89052, United States

  • Derm Research Institute, PLC

    RECRUITING

    Caledonia, Michigan, 49316, United States

  • Harrison Dermatology

    RECRUITING

    Missouri City, Texas, 77459, United States

  • Las Vegas Dermatology

    RECRUITING

    Las Vegas, Nevada, 89144, United States

  • StracSkin, PLLC

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • U.S. Dermatology Partners

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • U.S. Dermatology Partners Lee's Summit

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • U.S. Dermatology Partners Rockville

    RECRUITING

    Rockville, Maryland, 20850, United States

  • Virginia Clinical Research, Inc

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • West Virginia Research Institute

    RECRUITING

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.